Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) chairman Cathal Friel speaks to Proactive’s Stephen Gunnion from New York, where he’s attending the HC Wainwright Conference, meeting investors and visiting OTC Markets after the company started trading on the OTCQB Venture Market in March.
Friel discusses Poolbeg’s strong cash position, the successful start of its first clinical trial in POLB 001 and the expansion of its portfolio through a number of in-licensing deals.
Investors should watch out for a number of near-term value inflection points expected by the end of the year and into 2023, he added.
#ProactiveInvestors #PoolbegPharma #AIM #OTCQB #POLB001
